The Clinicopathological Features of Ganglioglioma with CD34 Expression and BRAF Mutation in Patients with Epilepsy

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2023 Mar 13

PMID 36910263

Authors

Ming-Guo Xie

Xiong-Fei Wang

Jiao Qiao

Jian Zhou

Yu-Guang Guan

Tian-Fu Li

Xue-Ling Qi

Guo-Ming Luan

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of the study was to evaluate the clinicopathological features, as well as the surgical prognosis, of epilepsy-associated gangliogliomas (GG) with CD34 expression and BRAF mutation.

Methods: Clinical data of patients who underwent epilepsy surgery for GG were retrospectively studied. Univariate and multivariate analyses were performed to evaluate the correlations of clinical and pathological factors with molecular markers of CD34 expression and BRAF mutation in GG.

Results: A total of 208 patients with GG had immunohistochemical detection of CD34 expression (positive/negative: 184/24), and among them, 89 patients had immunohistochemical detection of BRAF mutation (positive/negative: 54/35). By univariate and multivariate analyses, seizure aura ( = 0.025), concordance of ictal electroencephalogram (EEG) findings ( = 0.045) and medial temporal tumor ( = 0.030) were found to be related to CD34 expression, but only hospitalization time ( = 0.042) was different for BRAF-mutated status. In addition, drug-resistant epilepsy ( = 0.040) and concordance of interictal EEG findings ( = 0.009) were found to be associated with tumor progression-free survival (PFS) in univariate analysis, but only concordance of interictal EEG findings was with significance in multivariate analysis. However, CD34 expression or BRAF mutation in GG was not found to be associated with surgical outcomes of seizure control and tumor PFS.

Conclusion: The CD34 expression or BRAF mutation in GG may partly influence the distribution of clinicopathological features of patients with epilepsy, but they may be not able to predict the surgical prognosis of seizure outcome and tumor recurrence.

Citing Articles

Pediatric cerebral ganglioglioma epilepsy surgery: enhancing seizure outcomes through optimized resection applying high-field intraoperative magnetic resonance imaging.

Kurzbuch A, Cooper B, Kitchen J, McLaren A, Tronnier V, Ellenbogen J Childs Nerv Syst. 2025; 41(1):110.

PMID: 39934322 DOI: 10.1007/s00381-025-06766-9.

References

Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M . Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. 2013; 125(6):891-900. DOI: 10.1007/s00401-013-1100-2. View

Zaky W, Patil S, Park M, Liu D, Wang W, Wani K . Ganglioglioma in children and young adults: single institution experience and review of the literature. J Neurooncol. 2018; 139(3):739-747. DOI: 10.1007/s11060-018-2921-6. View

Slegers R, Blumcke I . Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. Acta Neuropathol Commun. 2020; 8(1):27. PMC: 7063704. DOI: 10.1186/s40478-020-00904-x. View

Deb P, Sharma M, Tripathi M, Chandra P, Gupta A, Sarkar C . Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol. 2006; 32(5):461-8. DOI: 10.1111/j.1365-2990.2006.00734.x. View

Sidney L, Branch M, Dunphy S, Dua H, Hopkinson A . Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014; 32(6):1380-9. PMC: 4260088. DOI: 10.1002/stem.1661. View

Giulioni M, Marucci G, Cossu M, Tassi L, Bramerio M, Barba C . CD34 Expression in Low-Grade Epilepsy-Associated Tumors: Relationships with Clinicopathologic Features. World Neurosurg. 2018; 121:e761-e768. DOI: 10.1016/j.wneu.2018.09.212. View

Zhang Y, Shen C, Guo Y, Zheng Y, Zhu J, Ding Y . BRAF V600E mutation in epilepsy-associated glioneuronal tumors: Prevalence and correlation with clinical features in a Chinese population. Seizure. 2016; 45:102-106. DOI: 10.1016/j.seizure.2016.12.004. View

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C . Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121(3):397-405. DOI: 10.1007/s00401-011-0802-6. View

Xing H, Song Y, Zhang Z, Koch P . Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis. J Mol Neurosci. 2021; 71(9):1815-1824. DOI: 10.1007/s12031-021-01837-3. View

10.

Guo Y, Lubbert M, Engelhardt M . CD34- hematopoietic stem cells: current concepts and controversies. Stem Cells. 2003; 21(1):15-20. DOI: 10.1634/stemcells.21-1-15. View

11.

Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G . Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011; 122(1):11-9. DOI: 10.1007/s00401-011-0841-z. View

12.

Blumcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien C . Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. N Engl J Med. 2017; 377(17):1648-1656. DOI: 10.1056/NEJMoa1703784. View

13.

Vornetti G, Marucci G, Zenesini C, de Biase D, Michelucci R, Tinuper P . Relationship among clinical, pathological and bio-molecular features in low-grade epilepsy-associated neuroepithelial tumors. J Clin Neurosci. 2017; 44:158-163. DOI: 10.1016/j.jocn.2017.06.022. View

14.

Chen X, Pan C, Zhang P, Xu C, Sun Y, Yu H . BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas. J Clin Neurosci. 2017; 46:50-57. DOI: 10.1016/j.jocn.2017.09.014. View

15.

Dougherty M, Santi M, Brose M, Ma C, Resnick A, Sievert A . Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 2010; 12(7):621-30. PMC: 2940652. DOI: 10.1093/neuonc/noq007. View

16.

Prabowo A, Iyer A, Veersema T, Anink J, Schouten-van Meeteren A, Spliet W . BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol. 2013; 24(1):52-66. PMC: 8029322. DOI: 10.1111/bpa.12081. View

17.

Reifenberger G, Kaulich K, Wiestler O, Blumcke I . Expression of the CD34 antigen in pleomorphic xanthoastrocytomas. Acta Neuropathol. 2003; 105(4):358-64. DOI: 10.1007/s00401-002-0652-3. View

18.

Lisievici A, Bohiltea R, Berceanu C, Lisievici M, Varlas V, Grigoriu C . Novel Perspectives Regarding CD34 Immunoexpression Patterns in Gangliogliomas. Curr Health Sci J. 2022; 47(4):523-528. PMC: 8987462. DOI: 10.12865/CHSJ.47.04.07. View

19.

Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A . Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol. 2013; 23(5):574-83. PMC: 8029244. DOI: 10.1111/bpa.12048. View

20.

Drosten M, Barbacid M . Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell. 2020; 37(4):543-550. DOI: 10.1016/j.ccell.2020.03.013. View